VectorY Strengthens Leadership Team with Appointment of Jim Scibetta as New CEO
VectorY Therapeutics announces Jim Scibetta as new CEO, while former CEO Sander van Deventer transitions to President of R&D. The company's lead program, VTx-002, a vectorized antibody targeting TDP-43 for ALS treatment, advances to IND-enabling studies following positive FDA feedback. The company recently completed a $138 million Series A funding round co-led by EQT Life Sciences and Forbion, and expanded its presence with a new office in Boston.
Scibetta brings over 20 years of executive leadership experience, including roles as CEO of Maverick Therapeutics and President of Pacira BioSciences. VTx-002 aims to delay ALS disease progression by targeting TDP-43 pathology and is expected to enter clinical trials by the end of 2025.
VectorY Therapeutics annuncia Jim Scibetta come nuovo CEO, mentre l'ex CEO Sander van Deventer passa a ricoprire il ruolo di Presidente della Ricerca e Sviluppo. Il programma principale dell'azienda, VTx-002, un anticorpo vettoriale che mira a TDP-43 per il trattamento della SLA, avanza verso studi abilitanti per la richiesta di indagine clinica (IND) dopo un feedback positivo da parte della FDA. L'azienda ha recentemente completato un round di finanziamento da 138 milioni di dollari Serie A co-guidato da EQT Life Sciences e Forbion, e ha ampliato la sua presenza con un nuovo ufficio a Boston.
Scibetta porta oltre 20 anni di esperienza nella leadership esecutiva, inclusi ruoli come CEO di Maverick Therapeutics e Presidente di Pacira BioSciences. VTx-002 mira a ritardare la progressione della SLA mirando alla patologia di TDP-43 ed è previsto che entri in sperimentazioni cliniche entro la fine del 2025.
VectorY Therapeutics anuncia a Jim Scibetta como nuevo CEO, mientras que el ex CEO Sander van Deventer pasa a ser Presidente de I+D. El programa principal de la compañía, VTx-002, un anticuerpo vectorizado dirigido a TDP-43 para el tratamiento de ELA, avanza hacia estudios que habilitarán la solicitud de nuevo fármaco IND tras recibir comentarios positivos de la FDA. La empresa completó recientemente una ronda de financiación de 138 millones de dólares en Serie A co-liderada por EQT Life Sciences y Forbion, y amplió su presencia con una nueva oficina en Boston.
Scibetta aporta más de 20 años de experiencia en liderazgo ejecutivo, incluyendo funciones como CEO de Maverick Therapeutics y Presidente de Pacira BioSciences. VTx-002 tiene como objetivo retrasar la progresión de la ELA al abordar la patología de TDP-43 y se espera que entre en ensayos clínicos a finales de 2025.
VectorY Therapeutics는 Jim Scibetta를 새로운 CEO로 발표하고, 이전 CEO인 Sander van Deventer는 R&D 대통령으로 전환됩니다. 회사의 주요 프로그램인 VTx-002는 ALS 치료를 위한 TDP-43을 타겟으로 하는 벡터화된 항체로, FDA의 긍정적인 피드백을 받은 후 IND 승인 연구로 나아가고 있습니다. 회사는 최근 EQT Life Sciences와 Forbion이 공동으로 주도한 1억 3천 8백만 달러 규모의 시리즈 A 자금 조달 라운드를 완료하고, 보스턴에 새로운 사무소를 열었습니다.
Scibetta는 Maverick Therapeutics의 CEO와 Pacira BioSciences의 대통령을 역임한 경영 리더십 경험이 20년 이상입니다. VTx-002는 TDP-43 병리를 겨냥하여 ALS 질병 진행을 지연시키는 것을 목표로 하며, 2025년 말까지 임상 시험에 들어갈 것이라고 예상됩니다.
VectorY Therapeutics annonce Jim Scibetta comme nouveau PDG, tandis que l'ancien PDG Sander van Deventer devient président de la R&D. Le programme phare de l'entreprise, VTx-002, un anticorps vecteur ciblant TDP-43 pour le traitement de la SLA, avance vers des études permettant d'obtenir une demande d'investigation clinique (IND) suite à des retours positifs de la FDA. L'entreprise a récemment achevé une levée de fonds de 138 millions de dollars en série A co-dirigée par EQT Life Sciences et Forbion, et a élargi sa présence avec un nouveau bureau à Boston.
Scibetta apporte plus de 20 ans d'expérience en leadership exécutif, y compris des rôles en tant que PDG de Maverick Therapeutics et président de Pacira BioSciences. VTx-002 vise à retarder la progression de la maladie SLA en ciblant la pathologie de TDP-43 et devrait entrer dans des essais cliniques d'ici la fin de 2025.
VectorY Therapeutics kündigt Jim Scibetta als neuen CEO an, während der ehemalige CEO Sander van Deventer zum Präsidenten für Forschung und Entwicklung wechselt. Das Leitprogramm des Unternehmens, VTx-002, ein vektorisiertes Antikörper, der TDP-43 für die Behandlung von ALS anvisiert, schreitet nach positivem Feedback von der FDA in IND-fähige Studien voran. Das Unternehmen hat kürzlich eine Finanzierungsrunde über 138 Millionen Dollar der Serie A abgeschlossen, die von EQT Life Sciences und Forbion co-leitet wurde, und seine Präsenz mit einem neuen Büro in Boston erweitert.
Scibetta bringt über 20 Jahre Erfahrung in der Geschäftsführung mit, darunter Positionen als CEO von Maverick Therapeutics und Präsident von Pacira BioSciences. VTx-002 zielt darauf ab, den Fortschritt der ALS-Krankheit zu verlangsamen, indem es die TDP-43-Pathologie anvisiert, und wird voraussichtlich bis Ende 2025 in klinische Studien eintreten.
- Secured $138 million Series A funding for clinical development
- Received favorable FDA feedback on VTx-002 pre-clinical package
- Clear timeline for clinical trials entry by end of 2025
- Geographic expansion with new Boston office
- Lead product VTx-002 still in pre-clinical phase
- Significant time before potential commercialization
- Former CEO, Sander van Deventer to become President of R&D
- Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package
-
Expansion of corporate footprint into the US (
Boston )
AMSTERDAM &
VectorY strengthens Leadership Team with appointment of Jim Scibetta as new CEO (Photo: Business Wire)
Former CEO and founder Sander van Deventer, will become President of R&D, and will continue to drive the development of VectorY’s pipeline including its lead program, VTx-002, a novel vectorized antibody targeting TDP-43 for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is currently in IND-enabling studies.
Concurrent with these activities, the Company has expanded its US presence by opening an office in
Strengthening the Leadership team
Mr. Scibetta brings more than 20 years of executive leadership experience, having built earlier stage companies focused on developing novel therapeutics for high unmet medical needs into mature biotechnology companies. Mr. Scibetta will also join the VectorY’s Board of Directors.
Adam Rosenberg, Chairman of VectorY Therapeutics said: “On behalf of the Board, I’m delighted to welcome Jim as our new CEO. He brings a significant degree of experience, vision and leadership which will play a critical role at this juncture of VectorY’s development as we advance our lead program. Jim’s experience complements and will build on the great progress that Sander and the VectorY team have achieved over the past four years. He will drive the Company towards its upcoming milestones while expanding its presence in the US.”
“I am excited about Jim joining the company as CEO. His experience of taking an innovative drug development pipeline and driving it forward is immensely valuable to VectorY as we approach the clinic,” added Sander van Deventer. “For VTx-002 in ALS, we recently received favorable FDA feedback regarding the sufficiency of our pre-clinical data package, our CMC requirements, and our proposed clinical protocol. It’s the perfect time for Jim to join and build out our team to facilitate rapid advancement of VTx-002 as well as the rest of our pipeline targeting neurodegenerative diseases”.
“I am delighted to join VectorY at such a pivotal time," said Jim Scibetta. "VectorY has impressive early data behind its technology and preclinical programs, and the Company is supported by a leading investor syndicate. There is a clear path to achieving clinical data for its lead asset, VTx-002, with considerable future potential from the pipeline emanating from the novel VectorY platform.” He added: “VTx-002 was designed by Sander and his team based on a deep understanding of both the underlying pathological drivers of this devastating disease, and the advancements in science and therapeutic modalities specifically needed to attack those unique disease drivers. I look forward to working with and building on the talented team at VectorY to continue the advancement of this new treatment."
Jim has served on numerous private and public company boards at value generating biotech companies, including CEO of Maverick Therapeutics leading to its 2021 acquisition by Takeda, President of Pacira BioSciences (Nasdaq: PCRX) during its growth from a clinical stage private company to a commercial stage public company worth more than
Prior to his biotech company-building career Mr. Scibetta spent 13 years in healthcare investment banking at Shattuck Hammond Partners and Paine Webber. He has an MBA from the University of
Advancing the pipeline and expanding the team
VectorY is developing a new vectorized antibody treatment for ALS. The aim for the program, VTx-002, is to significantly delay disease progression and preserve quality of life in the majority of ALS patients by targeting the underlying TPD-43 pathology.
VTx-002, currently in IND-enabling studies, selectively clears misfolded and aggregated TDP-43 from the cytoplasm of neuronal cells. Thereby, it restores the essential function of TDP-43 in the nucleus leading to preservation of neuronal cell function and health.
The Company has recently received favorable FDA feedback regarding the sufficiency of the pre-clinical data package, CMC requirements, and the proposed clinical protocol. The aim is for the program to enter the clinic by the end of 2025.
In November 2023, VectorY completed a
The Company is headquartered in
About VectorY
VectorY is on a mission to provide patients with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing and neuroscience drives the rapid development of much needed disease-modifying therapies for neurodegenerative diseases such as ALS. For more information, see www.VectorYtx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241216441837/en/
VectorY Therapeutics B.V.
Jim Scibetta, CEO
Elena Ritsou, CCO
E-mail: info@vectorytx.com
Tel: +31 681 174 072
Vigo Consulting (Media)
Melanie Toyne-Sewell / Rozi Morris
VectorY@vigoconsulting.com
Tel: +44 7890 022 814
Source: VectorY Therapeutics
FAQ
When will VectorY's VTx-002 enter clinical trials for ALS treatment?
How much funding did VectorY raise in its Series A round?
What is VectorY's VTx-002 targeting in ALS treatment?
What is Jim Scibetta's previous experience in biotech?
